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Abstract
Myelodysplastic syndromes (MDS) are in the majority of cases characterized by anemia. Both anemia and MDS per se may 
directly contribute to impairments in health-related quality of life (HRQoL). In this study, we aimed to investigate the anemia-
independent impact of MDS on HRQoL. We evaluated participants (≥ 50 years) from the large population-based Lifelines 
cohort (N = 44,694, mean age 59.0 ± 7.4 years, 43.6% male) and the European MDS Registry (EUMDS) (N = 1538, mean 
age 73.4 ± 9.0 years, 63.0% male), which comprises a cohort of lower-risk MDS patients. To enable comparison concerning 
HRQoL, SF-36 scores measured in Lifelines were converted to EQ-5D-3L index (range 0–1) and dimension scores. Lower-
risk MDS patients had significantly lower HRQoL than those from the Lifelines cohort, as illustrated in both the index score 
and in the five different dimensions. Multivariable linear regression analysis demonstrated that MDS had an adjusted total 
impact on the EQ-5D index score (B =  − 0.12, p < 0.001) and an anemia-independent “direct” impact (B =  − 0.10, p < 0.001). 
Multivariable logistic regression analysis revealed an anemia-independent impact of MDS in the dimension mobility, self-
care, usual activities, and anxiety/depression (all except pain/discomfort). This study demonstrates that the major part of 
the negative impact of lower-risk MDS on HRQoL is not mediated via anemia. Thus, the therapeutic focus should include 
treatment strategies directed at underlying pathogenic mechanisms to improve HRQoL, rather than aiming predominantly 
at increasing hemoglobin levels.
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Introduction
Myelodysplastic syndromes (MDS) are acquired clonal 
disorders of the hematopoietic stem cell, which are char-
acterized by bone marrow failure resulting in blood cyto-
penias. Anemia is the most prevalent cytopenia and is the 
most common objective disease manifestation [1, 2]. Sev-
eral studies have been conducted to assess health-related 
quality of life (HRQoL) in patients with MDS. HRQoL 
is usually decreased in patients with MDS and is associ-
ated with an unfavorable survival [3, 4]. A previous study 
comparing HRQoL in newly diagnosed individuals with 
lower-risk MDS (LR-MDS) (N = 1690) demonstrated 
that a significant proportion of MDS patients experience 
profound age- and sex-dependent restrictions in different 
HRQoL dimensions [5].
Patients with MDS are classified into subgroups based 
on several biological parameters to predict overall survival 
and the risk of transformation to acute myeloid leukemia 
(Revised International Prognostics Scoring System; IPSS-
R). Especially individuals with higher IPSS-R risk MDS 
have a poor prognosis [6, 7]. Intervention goals differ 
between IPSS-R risk groups. Treatment for patients with 
LR-MDS is focused on restoration of cytopenias, to delay 
progression to acute myeloid leukemia and prolonging sur-
vival [8]. The only curative option is hematopoietic cell 
transplantation [1]. Due to advanced age and/or co-exist-
ing medical conditions, patients are often ineligible for 
this procedure. Therefore, treatment decisions for lower 
risk IPSS-R MDS often focus on improvement of quality 
of life (QoL) [9].
Anemia, especially anemia of chronic inflammation, has 
been associated with a decreased HRQoL in older indi-
viduals in the general population [10]. In MDS patients, 
both anemia and other anemia-independent characteristics 
of MDS may have a direct contribution to impairments 
in HRQoL. There is conflicting evidence on the impact 
of hemoglobin levels on QoL in MDS, whereas chronic 
RBC transfusion dependency is clearly associated with 
an inferior QoL [11]. Steensma et al. demonstrated a poor 
correlation between hemoglobin levels and fatigue in 
MDS patients (N = 359). However, the influence of prior 
RBC transfusions on the evaluated hemoglobin levels was 
uncertain [12]. In another study (N = 280), the degree of 
anemia was associated with, but could not fully explain, 
the subjective perception of fatigue [13]. In smaller studies 
(N = 50 and N = 39), lower hemoglobin levels were associ-
ated with fatigue and poorer QoL [14, 15]. Further, inter-
vention studies do not convincingly prove that interven-
tions that aim to increase the hemoglobin levels in MDS 
patients have a beneficial effect on HRQoL [16, 17].
Since hemoglobin levels may not be the main determinant 
of HRQoL in MDS patients, studies assessing the impact 
of other mechanisms are warranted [18]. In this study, we 
aimed to investigate the anemia-independent impact of LR-
MDS on HRQoL, using the European MDS (EUMDS) Reg-
istry, and the Lifelines cohort.
Methods
Study design
First, we analyzed data from the EUMDS Registry, a non-
interventional longitudinal study, enrolling newly diag-
nosed patients with MDS (IPSS low or intermediate-1) 
from 148 hematology centers in 16 European countries and 
Israel (started in 2007). Enrollment was within 100 days 
of the diagnostic bone marrow aspirate. The study has 
been approved by the local ethics committees and written 
informed consent was obtained from all participants. The 
study has been performed in accordance with the Decla-
ration of Helsinki. Details of this cohort and the recorded 
clinical parameters have been described elsewhere [4, 5]. 
For the current analysis, we used data from the baseline sur-
vey and excluded participants younger than 50 years and 
those with missing data on HRQoL or hemoglobin level. 
Individuals who received a RBC transfusion within 30 days 
before the blood sample was taken were also excluded. In 
total, 1538 EUMDS patients were eligible for analysis. Sec-
ond, we analyzed data from the Lifelines cohort. Lifelines 
is a multi-disciplinary prospective population-based cohort 
study examining in a unique three-generation design the 
health and health-related behaviors of 167,729 persons liv-
ing in the North of The Netherlands. It employs a broad 
range of investigative procedures in assessing the biomedi-
cal, socio-demographic, behavioral, physical, and psycho-
logical factors which contribute to the health and disease 
of the general population, with a special focus on multi-
morbidity and complex genetics. The local ethics committee 
approved the research protocol, and informed consent was 
signed by every participant [19, 20]. At baseline, all subjects 
completed a self-administered questionnaire, amongst others 
on medical history, past and current diseases, use of medica-
tion, and quality of life. For the present study, we included 
44,694 subjects of ≥ 50 years from whom data on HRQoL 
and hemoglobin level were available. Data about red blood 
cell transfusions were not available for Lifelines participants.
Laboratory parameters
In Lifelines, blood samples were collected in the morning 
after an overnight fast. The blood samples were placed at 
4 °C and transported from the Lifelines research site to the 
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Lifelines laboratory, under tightly controlled and continu-
ously monitored conditions. From the Lifelines laboratory, 
part of the samples were directly transferred to the central 
laboratory of the University Medical Center Groningen, 
to perform routine clinical chemistry assays on fresh sam-
ples. Hemoglobin, total leucocytes, and thrombocytes were 
measured using routine procedures on a XE2100-system 
(Sysmex, Japan). In EUMDS, a complete blood count was 
performed at entry of the study as part of routine clinical 
care in the local hospital.
Scoring of comorbidities
In the EUMDS Registry, comorbidity was scored using the 
Hematopoietic Cell Transplantation-Comorbidity Index 
(HCT-CI) and the Myelodysplastic Syndrome-Comorbidity 
Index (MDS-CI). The HCT-CI was developed by Sorror 
et al. and comprises 17 groups of diseases [21, 22]. The 
MDS-CI was created using the five significant HCT-CI dis-
ease groups associated with non-leukemic deaths (cardiac 
disease (2 points), hepatic disease (1 point), pulmonary dis-
ease (1 point), renal disease (1 point), and solid tumor (1 
point)) in a population of MDS patients. The final scores 
are low (0 points), intermediate (1 or 2 points), or high (3 or 
more points) [23]. Comorbidity index scores were generated 
based on information given by physicians in the EUMDS 
registry, and based on self-report combined with verified 
medication use (scored by ATC code) and laboratory data in 
the Lifelines cohort. Participants in the Lifelines cohort may 
suffer from a wide range of medical issues since only indi-
viduals with a limited life expectancy or severe psychiatric/
physical illness were excluded from participation [24]. The 
used definitions are listed in Table S1. Complete data were 
available for 15,784 Lifelines and 1157 EUMDS partici-
pants. Demographic characteristics between individuals with 
and without information available to generate the MDS-CI 
did not relevantly differ in both cohorts.
Health‑related quality of life
In EUMDS, HRQoL was measured by the EuroQol Five-
Dimensional Questionnaire (EQ-5D-3L). The EQ-5D-3L is 
a commonly used, generic HRQoL questionnaire consisting 
of a descriptive part and a visual analogue scale (VAS). The 
descriptive part consists of five dimensions related to daily 
activities (mobility, self-care, usual activities, pain/discom-
fort, and anxiety/depression), with three response categories 
(no problems, moderate problems, or severe problems) [25]. 
These questions provide 243 possible health states from 
which an index score (generally ranging from 0–1) can be 
calculated [26]. The current analyses were performed using 
the UK value set [27]. In Lifelines, HRQoL was measured 
using the RAND 36-Item Health Survey (Dutch version of 
the Short-Form 36 (SF-36) questionnaire). This generic 
questionnaire consists of 36 items in eight dimensions: 
physical functioning (10 items), physical role functioning (4 
items), bodily pain (2 items), general health (5 items), vital-
ity (4 items), social functioning (2 items), emotional role 
functioning (3 items), and mental health (5 items). Dimen-
sion scores (range 0–100) on the eight domains were gener-
ated [28]. A higher score reflects a better health status and 
well-being in both questionnaires. The SF-12 is a shortened 
version of the SF-36, including 12 of the 36 questions [29].
Conversion of SF‑36 to EQ‑5D
To enable comparisons between HRQoL measured in 
EUMDS and in Lifelines, the SF-36 data (and derived SF-12 
data) were converted to EQ-5D data in two approaches. In 
the first approach, domain scores of the SF-36 questionnaire 
were converted into a preference-based EQ-5D index score 
following the mapping algorithm of Rowen et al. (random 
effects generalized least squares model 3) [30]. In the sec-
ond approach, the multinomial response mapping algorithm 
developed by Gray et al. was used to estimate the probability 
of a score within one of the three response categories of the 
EQ-5D for each dimension based on the SF-12 results [31].
Statistical analysis
Data were presented as mean (standard deviation), 
median (interquartile range), or percentage. We evalu-
ated between-group differences using one-way ANOVA, 
Kruskal–Wallis test, or Chi-square test, as appropriate. 
Anemia was defined according to the WHO criteria as a 
hemoglobin level < 13.0 g/dL in men and < 12.0 g/dL in 
women [32]. Following best practice recommendations for 
observational studies [33], a simple causal diagram was 
derived by an expert panel of epidemiologists and clinical 
experts (authors) to explicitly present the prior assump-
tions based on literature in order to derive the causal 
effect of MDS on HRQoL [5]. The causal directed acyclic 
graph (DAG) for the study is presented in Fig. 1. Based 
on the causal DAG, confounders (i.e., common causes of 
(severity of) MDS and HRQoL) were selected prior to the 
analysis. Multivariable linear regression analyses (for the 
outcome EQ-5D index score) and logistic regression anal-
yses (for the outcomes EQ-5D domains; problems (moder-
ate or severe) versus no problems) were used to examine 
both the total and the anemia-independent impact of MDS 
on HRQoL. First, a crude (unadjusted) analysis for the 
association between MDS and HRQoL was performed 
(model 1). Model 2 was adjusted for the confounders age 
(50–60/61–75/ > 75 years), sex, comorbidity (MDS-CI 
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low/intermediate/high), and prior RBC transfusions, in 
order to assess the total causal impact of MDS on HRQoL. 
In model 3, we additionally controlled for the mediator 
anemia to assess the (“direct”) causal impact of MDS on 
HRQoL that is not mediated via anemia. Lastly, in model 
4 we added hemoglobin levels to the model. Participants 
were eligible for inclusion in the EUMDS registry when 
they had a low or intermediate‐1 risk score according to 
the IPSS. From 2012, IPSS‐R scores were retrospectively 
assigned by one of the investigators of the EUMDS regis-
try and verified by an independent expert of the interna-
tional IPSS working group of the MDS Foundation [4]. As 
sensitivity analysis, the analyses were repeated excluding 
individuals who were retrospectively classified as IPSS-
R intermediate, high or very high risk (N = 205), or who 
had an unknown IPSS-R (N = 142), and individuals who 
ever received a RBC transfusion (N = 313). Unstandard-
ized regression coefficients and odds ratios are reported 
with 95% confidence intervals. All statistical tests were 
performed two-sided and a p-value < 0.05 was considered 
significant. Data were analyzed using IBM SPSS software, 
version 23.0.
Results
Relevant baseline characteristics for both anemic and non-
anemic participants from the population-based Lifelines 
cohort and EUMDS cohort are shown in Table 1. Partici-
pants from the EUMDS cohort were significantly older, 
were more often male, and revealed a higher comorbidity 
burden compared with the Lifelines participants. Anemia 
was present in 89.2% of EUMDS participants in contrast 
to 2.9% in individuals of Lifelines. In both cohorts, ane-
mic participants were older than non-anemic individuals, 
whereas in the Lifelines cohort, there was a higher per-
centage of anemic females. Anemic EUMDS participants 
had significantly lower mean hemoglobin levels than ane-
mic Lifelines participants.
The EUMDS cohort was characterized by a mean 
EQ-5D index score of 0.74 (± 0.27), whereas the mean 
EQ-5D index score in the Lifelines cohort was 0.90 
(± 0.10) (P < 0.001) (Table S2). Likewise, a significantly 
larger percentage of EUMDS participants reported moder-
ate to severe problems in all five EQ-5D dimensions com-
pared to individuals from the Lifelines cohort (Fig. 2a). 
The most pronounced differences were observed in the 
dimensions mobility and usual activities. Smaller differ-
ences were observed in the dimensions self-care, pain/
discomfort, and anxiety/depression.
A lower EQ-5D index score as well as a larger percent-
age of individuals with moderate to severe problems was 
observed in females, at advanced age, and in individuals 
with an increased comorbidity burden in all five EQ-5D 
dimensions in both cohorts, except for the dimension 
anxiety/depression in the EUMDS cohort. In this dimen-
sion a larger proportion of problems was only observed 
in females compared to males and no significant differ-
ences related to age or comorbidity burden were present 
(Table S2), Furthermore, a significantly lower index score 
and a larger percentage of participants with moderate to 
severe problems in all five dimensions were detected 
in anemic participants as compared to non-anemic par-
ticipants in both cohorts, being more pronounced in the 
EUMDS cohort (Fig. 2b and Table S2).
To assess the anemia-independent impact of MDS on 
HRQoL, univariable and multivariable linear and logis-
tic regression analyses were performed. Univariable lin-
ear regression analysis demonstrated a significant nega-
tive association between MDS and EQ-5D index scores 
in the crude analysis (model 1, B =  − 0.16). MDS had 
an adjusted (causal) total impact on HRQoL (model 2, 
B =  − 0.12) and an anemia-independent “direct” impact 
(model 3, B =  − 0.11), independent of age, sex, comor-
bidity, and prior RBC transfusions. Since the hemoglobin 
levels differed significantly between anemic individuals 
Fig. 1  Directed acyclic graph for the assessment of the total and ane-
mia-independent impact of lower-risk myelodysplastic syndromes on 
health-related quality of life. This causal diagram encodes the prior 
assumptions on common causes of (increase in severity of) MDS and 
HRQoL as well as direct and indirect causal pathways from MDS to 
HRQoL. The four confounders may also influence anemia; the related 
arrows have been left out for simplified visualization but are fully 
considered in the analyses. HRQoL, health-related quality of life; 
MDS, myelodysplastic syndromes; RBC, red blood cell
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in both cohorts, in model 4, we additionally adjusted for 
hemoglobin levels, which did not change the impact as 
present in model 3 (model 4, B =  − 0.10) (Table 2). Our 
results indicated that the presence of MDS was associated 
with a decrease of EQ-5D index score of 0.10 on a range 
of 0 − 1, independent of anemia.
Subsequently, logistic regression analysis was performed 
to assess the anemia-independent impact on the five EQ-5D 
Table 1  Baseline characteristics of the Lifelines cohort and the EUMDS cohort
Data are given as mean ± SD or percentage. aMDS-CI was available in 516 anemic Lifelines participants, in 15,268 non-anemic Lifelines par-
ticipants, in 1037 anemic EUMDS participants and in 120 non-anemic EUMDS participants. MDS-CI, myelodysplastic syndromes comorbidity 
index; NA, not applicable; RBC, red blood cell; SD, standard deviation
Lifelines participants EUMDS participants Life-
lines vs. 
EUMDS













Age  < 0.001  < 0.001  < 0.001
  50–60 years 
(%)
56.0 57.0 56.0 9.3 8.7 14.5
  61–75 years 
(%)
41.5 37.3 41.6 45.3 44.0 56.0
   > 75 years 
(%)
2.5 5.7 2.4 45.4 47.3 29.5
Male (%) 43.6 26.9 44.1  < 0.001 63.0 63.0 62.7 0.92  < 0.001
Hemoglobin level (g/dL)
  Male 15.0 ± 1.0 12.2 ± 0.7 15.1 ± 0.9  < 0.001 10.6 ± 1.9 10.2 ± 1.5 14.0 ± 0.9  < 0.001  < 0.001
  Female 13.6 ± 0.9 11.3 ± 0.8 13.7 ± 0.8  < 0.001 10.1 ± 1.6 9.8 ± 1.2 13.0 ± 0.7  < 0.001  < 0.001
RBC transfu-
sion (%)
NA NA NA NA 20.4 22.6 1.8  < 0.001 NA
MDS-CIa (%) 0.21 0.39  < 0.001
  Low 78.1 75.0 78.2 61.7 61.1 66.7
  Intermediate 20.2 23.3 20.1 32.9 33.3 30.0
  High 1.7 1.7 1.7 5.4 5.6 3.3
Fig. 2  Percentage of individuals with moderate to severe problems in 
the five EQ-5D dimensions according to cohort and presence of ane-
mia. Panel a shows the percentage of individuals with moderate to 
severe problems in the five EQ-5D dimensions according to cohort 
(EUMDS or Lifelines). Panel b shows the percentage of individu-
als with moderate to severe problems in the five EQ-5D dimensions 














Table 2  The total and anemia-independent “direct” impact of lower-risk myelodysplastic syndromes and the impact of anemia on HRQoL (EQ-5D index score) based on univariable and multi-
variable linear regression analyses
Model 1 was a crude analysis. Model 2 was adjusted for age (50–60 years, 61–75 years, or 75 years and older), sex, comorbidity (MDS-CI low, intermediate, high), and prior RBC transfu-
sions. Model 3 was additionally adjusted for anemia. Model 4 was additionally adjusted for hemoglobin levels. Anemia was defined as a hemoglobin level < 13.0 g/dL in men and < 12.0 g/dL in 
women. B, unstandardized regression coefficient; β, standardized regression coefficient; MDS, myelodysplastic syndromes; MDS-CI, myelodysplastic syndromes comorbidity index; RBC, red 
blood cell; Ref, reference; SE, standard error
EQ-5D index score
Model 1 (crude association) Model 2 (total causal impact) Model 3 (“direct” causal impact) Model 4 (“direct” causal impact)
B SE β P value B SE β P value B SE β P value B SE β P value
MDS (y/n)  − 0.163 0.003  − 0.259  < 0.001  − 0.119 0.004  − 0.243  < 0.001  − 0.106 0.006  − 0.215  < 0.001  − 0.104 0.006  − 0.212  < 0.001
Anemia (y/n)  − 0.016 0.005  − 0.038  < 0.001  − 0.013 0.005  − 0.031 0.012
Hemoglobin level (g/dL) 0.001 0.001 0.015 0.23
Age group
  50–60 years Ref Ref Ref
  61–75 years 0.005 0.002 0.019 0.009 0.005 0.002 0.019 0.009 0.005 0.002 0.019 0.009
   > 75 years 0.037 0.005  − 0.066  < 0.001  − 0.036 0.005  − 0.064  < 0.001  − 0.036 0.005  − 0.064  < 0.001
Sex (female)  − 0.028 0.002  − 0.112  < 0.001  − 0.028 0.002  − 0.110  < 0.001  − 0.026 0.002  − 0.104  < 0.001
MDS-CI
  Low Ref Ref Ref
  Intermediate  − 0.037 0.002  − 0.121  < 0.001  − 0.037 0.002  − 0.120  < 0.001  − 0.037 0.005  − 0.121  < 0.001
  High  − 0.089 0.006  − 0.100  < 0.001  − 0.089 0.006  − 0.100  < 0.001  − 0.089 0.006  − 0.100  < 0.001
RBC transfusion (y/n)  − 0.077 0.008  − 0.074  < 0.001  − 0.075 0.008  − 0.072  < 0.001  − 0.073 0.009  − 0.070  < 0.001
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dimensions. In the univariable analysis (model 1), assess-
ing the unadjusted association between MDS and HRQoL, 
MDS was strongly associated with decreased HRQoL in 
four dimensions (all except pain/discomfort). Multivariable 
regression revealed a significant total adjusted impact of 
MDS (model 2) in the dimension mobility, self-care, usual 
activities, and anxiety/depression. Furthermore, increasing 
age (> 75 years), being female, having a higher MDS-CI, and 
prior RBC transfusion negatively impacted HRQoL. How-
ever, increasing age was associated with less problems in the 
dimension anxiety/depression. In model 3, we additionally 
controlled for the mediator anemia, to assess the “direct” 
causal impact of MDS on the HRQoL dimensions that is 
not mediated via anemia. An anemia-independent impact 
of MDS was demonstrated in the same four dimensions; 
mobility, self-care, usual activities, and anxiety/depression. 
Additionally, controlling for hemoglobin levels (model 4) 
decreased the odds ratio’s in the dimensions self-care and 
usual activities, whereas the odds ratios in the dimensions 
mobility and anxiety/depression were comparable. Anemia 
(model 4) had only a residual significant impact on HRQoL 
in the dimension mobility (Fig. 3 and Table S3). A higher 
hemoglobin level (per g/dL) was associated with a lower 
percentage of participants with moderate to severe problems 
in the dimensions self-care and usual activities. Sensitivity 
analysis restricted to individuals with IPSS-R (very) low 
risk and without RBC transfusions did not materially alter 
the described associations (Table S4).
Fig. 3  Forest plot showing the total and anemia-independent impact 
of lower-risk myelodysplastic syndromes and the impact of anemia 
on health-related quality of life. Forest plots indicating the odds ratio 
(circles) and 95% confidence intervals (error bars) of having moder-
ate to severe problems in the five dimensions of the EQ-5D as crude 
association between MDS and HRQoL (blue, model 1), total causal 
impact of MDS on HRQoL (blue, model 2), anemia-independent 
“direct” causal impact of MDS (blue, model 3 and 4), and impact 
of anemia (red, model 3 and 4). Model 1 was an unadjusted (crude) 
analysis. Model 2 was adjusted for age (50–60  years, 61–75  years, 
or 75  years and older), sex, comorbidity (MDS-CI low, intermedi-
ate, high), and prior red blood cell transfusions. Model 3 was addi-
tionally adjusted for anemia. Model 4 was additionally adjusted for 
hemoglobin levels. CI, confidence interval; MDS, myelodysplastic 
syndromes
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Discussion
Combining data from a large number of newly diagnosed 
LR-MDS patients and a large general population-based 
cohort, we confirmed the negative impact of LR-MDS on 
HRQoL, which was particularly present in the dimension 
mobility, usual activities, self-care, and anxiety/depres-
sion. This study is the first to assess the anemia-independ-
ent impact of LR-MDS on HRQoL and demonstrates that 
the major part of the negative impact is not mediated via 
anemia. After correction for hemoglobin levels, only the 
dimension mobility was negatively affected by anemia. 
Previous studies focused on demonstrating the nega-
tive impact of MDS in general on HRQoL, while others 
assessed the impact of anemia and hemoglobin levels 
on HRQoL in MDS patients, with conflicting results [5, 
12–15].
The anemia-independent negative impact of LR-MDS 
was mainly present in HRQoL dimensions which reflect 
capacities that are essential for living independently 
and maintaining social well-being, whereas there was 
no impact in the dimension pain/discomfort. Especially, 
the strong impact in the dimension self-care is clinically 
important, since problems in this dimension are rare in the 
general population. The impact shown in these dimensions 
is in line with the fact that fatigue is the most prevalent 
symptom of MDS [12, 13, 34] and is known to be sig-
nificantly related to activities of daily living [35]. Addi-
tionally, patients with fatigue experience greater overall 
symptom burden, particularly loss of appetite, dyspnea, 
insomnia, and pain [13]. The impact of LR-MDS on anxi-
ety/depression decreased when adjusted for age. This may 
be explained by the known inverse relationship between 
emotional distress and age in cancer patients. It has been 
hypothesized that older individuals might be cognitively 
and emotionally better prepared to accept illness [36].
The small residual impact of anemia in LR-MDS on 
HRQoL was present in the dimension mobility, whereas 
hemoglobin levels were associated with HRQoL dimen-
sions self-care and usual activities. This is in line with 
the impact of anemia in older individuals from the gen-
eral population, which is also mainly present in dimen-
sions representing physical functioning [10]. It could be 
hypothesized that the relative effect of anemia on HRQoL 
might be smaller due to the frequent co-existing mor-
bidities in older MDS patients. In current guidelines for 
symptomatic LR-MDS patients with anemia, treatment 
modalities which aim to increase hemoglobin levels are 
the first choice [1]. Treatment selection depends on the 
del(5q) status, the transfusion need, and serum EPO lev-
els. Treatment options include erythropoiesis-stimulating 
agents, granulocyte-colony-stimulating factor (G-CSF), 
erythropoiesis-maturating agents (luspatercept for MDS 
with ring sideroblasts, FDA and EMA approved), or 
immunomodulatory drugs (for MDS with 5q-), which 
all may be combined with supportive RBC transfusions. 
Patient‐reported outcome measures, such as HRQoL, are 
used to assess the effectiveness of an intervention meas-
ured from the patient perspective [37]. However, clinical 
trials assessing these treatment options are not conclu-
sive. A randomized controlled trial assessing the effect of 
erythropoietin and G-CFS compared to best supportive 
care did not show a difference in HRQoL between both 
treatment groups [16]. In contrast, in a prospective study, 
responders to erythropoietin in combination with G-CSF 
were shown to have better HRQoL [38]. On the other hand, 
no beneficial effect on HRQoL of darbepoetin compared to 
only supportive care was demonstrated [17]. For asymp-
tomatic LR-MDS patients with anemia, watchful waiting 
is currently recommended. Data from the current study 
suggest that concerning HRQoL, regardless of anemia 
status, future studies are needed to identify underlying 
pathophysiological mechanisms.
In recent years, accumulating evidence has indicated 
that dysregulation of the immunological environment has 
an important role in the pathogenesis of MDS [39]. A recent 
meta-analysis demonstrated increased levels of TNF‐α, IL-6, 
and IL-8 and decreased levels of IL-17 in individuals with 
MDS as compared to controls [40]. Several studies assessed 
the impact of inflammation on HRQoL/self-rated health in 
older individuals from the general population, showing in 
general a negative impact. Those studies included different 
biochemical markers of inflammation, e.g., pro-inflamma-
tory cytokines (including IL-6 and TNF-α) [41–43], acute-
phase proteins [42–44], or white blood cell counts [45]. In 
MDS, elevated levels of IL-6 and IL-1 receptor antagonist 
and TNF‐α were associated with worse HRQoL [46]. Given 
the association between inflammation, anemia, and HRQoL, 
targeting systemic inflammation may be an encouraging 
therapeutic possibility [10, 47]. For example, treatment 
with lenalidomide, which modulates different components 
of the immune system including altering cytokine produc-
tion [48], has been demonstrated to be associated with 
improved HRQoL [49–51]. However, it should be noted 
that improved HRQoL was associated with an increase in 
hemoglobin level. Other treatment modalities targeting the 
immune system are currently under study [52]. Furthermore, 
it has been demonstrated in older patients with hematologi-
cal malignancies that individuals with malnutrition had more 
often inflammation (as measured by elevated CRP and low 
albumin) and suffered from impairments in mood, perfor-
mance status, and fatigue [18]. Alternatively, the anemia-
independent impaired HRQoL in MDS patients could partly 
be explained by the knowledge of having a (pre-)malignant 
disorder [36, 53, 54], which is supported by the impact of 
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LR-MDS on the HRQoL dimension anxiety/depression, irre-
spective of anemia status.
The major strength of this first study assessing the ane-
mia-independent impact of LR-MDS on HRQoL is the use 
of data from a large MDS registry and a large general popu-
lation-based cohort. We were able to link data of two well-
characterized study cohorts. Another strength is the explicit 
reporting of our causal assumptions via a causal diagram 
[33]. This helps to better understand the different compo-
nents of causal pathways and potential biases. In addition, 
the huge confounding bias by age, sex, comorbidity, and 
prior RBC transfusions encoded in the causal diagram is 
made explicit in Fig. 3 by contrasting the crude (model 1) 
and confounder-adjusted (model 2) impact estimates. This 
causal logic supports the plausibility of our results.
Several limitations should be acknowledged. First, 
HRQoL was assessed using two different general HRQoL 
questionnaires. By the absence of a cohort including both 
individuals with MDS and individuals from the general 
population in which HRQoL was assessed using the same 
instrument and of whom medical data are available, we used 
published mapping algorithms to convert the Lifelines data 
into a summary EQ-5D index score and into scores for the 
five EQ-5D dimensions. As these mapping algorithms are 
not perfect, this may have led to measurement bias. On the 
other hand, the performance of the mapping algorithms is 
best in the range of EQ-5D index scores relevant for the 
Lifelines cohort. Absolute estimation errors in the model 
dataset of the mapping algorithms are smaller than the dif-
ferences between the two cohorts in this study. Using these 
algorithms allowed not only the comparison of the overall 
HRQoL represented by the EQ-5D index but also compari-
son of mobility, self-care, usual activities, pain/discomfort, 
and anxiety/depression. A second limitation is that the 
assessment of comorbidities differed between the cohorts. 
In the EUMDS cohort, comorbidity was scored according 
to a physician’s evaluation, whereas in the Lifelines cohort, 
MDS-CI was mainly based on (verified) medication use and 
self-reported disorders. Validation studies have shown sub-
stantial agreement between self-report questionnaires and 
medical record data [55–57], but over- or underestimation 
of the real prevalence cannot be excluded. Third, individuals 
with a RBC transfusion in the last 30 days were excluded to 
capture the unmasked impact of anemia, which may have led 
to selection bias. Fourth, since biochemical measurements 
associated with inflammation (e.g., CRP or ferritin) or with 
the type of anemia were only available in a minority of the 
participants, we were not able to study their relation with 
HRQoL in the context of MDS. Fifth, as in all observational 
studies, residual confounding by unknown or unmeasured 
confounders or the presence of time-varying confound-
ing may bias results [58]. Sixth, there may be additional 
confounders for the relation between anemia and HRQoL 
beyond the ones we have adjusted for, which may complicate 
the “direct” impact estimation. Seventh, there is an ongo-
ing debate on the interpretation of total and “direct” causal 
impacts of disease characteristics, as changing those needs 
well-defined interventions. Therefore, our results should be 
interpreted with caution, merely indicating potential causal 
pathways that should not be overlooked when optimizing 
treatment of MDS. Finally, our study is restricted to LR-
MDS and cannot be generalized to all subtypes of MDS.
In conclusion, this study presents the first large-scale 
assessment of the anemia-independent impact of LR-MDS 
on HRQoL. Our data indicate that the major part of the 
negative impact of LR-MDS on HRQoL, particularly in the 
dimensions mobility, usual activities, self-care, and anxiety/
depression, is not mediated via anemia. Thus, the therapeutic 
focus should include treatment strategies directed at underly-
ing pathogenic mechanisms to improve HRQoL, rather than 
aiming predominantly at increasing hemoglobin levels.
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